The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. (MYGN), Tuesday announced a five-year partnership to boost the clinical evaluation and development of the latter's molecular residual disease or MRD assay.
Under the collaboration, the parties will explore how ultrasensitive Precise MRD tests can enhance treatment strategies for providers and improve patient outcomes.
Moreover, the parties will design both retrospective and prospective studies to investigate the tests utility in breast, gastrointestinal, genitourinary, and gynecological cancers.
Currently, Myriad Genetics's stock is trading at C$0.43, up 7.5 percent on the Canadian Sec-Free Realtime.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.